Tinidazol

Quick links to important sections

Tinidazol

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tinidazol

Quick Facts Overview

Property Description
Active ingredient Tinidazole (INN)
Form Oral tablets; Compounded oral suspension
Pharmacological class Nitroimidazole (Anti-infective)
General Purpose Targeting anaerobic pathogens and protozoa
Origin Synthetic compound

Composition and Classification

Tinidazol is a potent, synthetic medicinal preparation whose active substance is Tinidazole (INN). It is classified pharmacologically as an anti-infective and belongs specifically to the nitroimidazole family of compounds. The product is manufactured for the oral route of administration and is typically provided as a single-entity product in tablet form.

The defining feature of tinidazole is its classification as a nitroimidazole derivative. This specific structure is essential for its function, providing the necessary chemical framework that allows the drug to become activated only inside the low-oxygen (anaerobic) environments where its target organisms thrive. Tinidazole is clinically recognized as an evolution of the nitroimidazole class, often utilized in treatment guidelines for its established pharmacokinetic profile compared to related agents. This distinction corresponds to its activity against susceptible protozoal and bacterial infections.


General Therapeutic Function

The core function of Tinidazole is to eradicate the specific populations of susceptible anaerobic pathogens and protozoa responsible for causing infection. Its mechanism of action ensures selective toxicity by damaging the genetic material of these microorganisms.

By interrupting the infectious cycle at the DNA level, Tinidazole effectively halts the proliferation and spread of the targeted agents. This critical action serves the broad goal of clearing the body of the targeted infectious organisms, confirming that the medicine serves as a focused tool for resolving infections caused by specific microbial life.

Regulatory References

  1. Tinidazole: MedlinePlus Drug Information

What side effects are possible with Tinidazol?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions of Tinidazole primarily within the Gastrointestinal and Nervous System Disorders categories. The overall safety profile, as outlined by government health authorities, is defined by the spectrum of these reported events and specific restrictions on use.


Adverse Reaction Frequencies

Classification Examples of Officially Documented Adverse Reactions
Common Metallic or bitter taste, nausea, fatigue, headache, vomiting, dyspepsia.
Rare Transient neutropenia, convulsions (seizures), peripheral neuropathy, severe acute hypersensitivity reactions (e.g., Stevens-Johnson Syndrome).

Serious Adverse Reactions and Safety Constraints

The development of peripheral neuropathy (sensory or motor) is a serious, rare adverse reaction that necessitates the discontinuation of treatment if neurological signs emerge, a constraint detailed in official labeling. Caution is advised for patients with pre-existing organic neurological disorders.

Safety constraints also explicitly prohibit the co-exposure of the medicine with alcohol. Alcoholic beverages must be strictly avoided during treatment and for at least 72 hours after the last dose to prevent a defined systemic reaction. Furthermore, use is contraindicated during the first trimester of pregnancy and is generally not recommended for patients with severe hepatic impairment, due to the potential for increased systemic exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Tinidazole establishes specific requirements for emergency action and defines the limitations in documented clinical data regarding overdose.

Documented Manifestations and Emergency Action Reports of overdose in humans are considered anecdotal, and the official prescribing information notes that there is no consistent data regarding the specific signs or symptoms of overdose. While a consistent profile is lacking, effects reported following excessive ingestion have included gastrointestinal symptoms, such as upset stomach and diarrhea, and localized reactions, such as skin rashes.

If an overdose is suspected, immediate medical attention is required. The government-stated guidance on when medical help must be urgently sought is triggered by severe clinical presentations. Emergency services must be called immediately if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.

Official Management and Antidote Status In terms of intervention, there is no specific antidote available for the treatment of Tinidazole overdosage. Management is explicitly defined as symptomatic and supportive. Official documentation mentions that procedural steps, such as gastric lavage, may be useful. Furthermore, the drug is officially noted to be easily dialyzable, confirming that hemodialysis is an established procedure for drug removal in cases where it is deemed necessary.

Therapeutic Uses of Tinidazol

What Tinidazole Treats: Main Uses and Benefits

Tinidazole is an antimicrobial agent that is generally used for managing infections caused by susceptible protozoa and certain anaerobic bacteria. Its clinical applications are relevant for managing conditions involving episodic or fluctuating manifestations.


The drug is commonly used across conditions presenting with acute episodes, where it helps address symptom clusters that may become intense or disruptive. It is applied in addressing conditions involving inflammatory or irritative processes such as trichomoniasis, giardiasis, amebiasis (both intestinal and liver), and bacterial vaginosis (BV). These conditions often cause symptoms related to physical discomfort and systemic imbalance.

Tinidazole provides supportive relief when symptoms interfere with routine activities and assists with maintaining functional stability. It is relevant in contexts involving heightened systemic burden and may be part of symptomatic management to help ease the overall symptom burden. One core benefit is that it:

“...supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Symptom Fluctuations
Tinidazole may assist with helping patients cope more steadily during periods where symptoms become temporarily overwhelming.

This supportive application contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed official label for Tinidazole

Eligibility and Restrictions for Use

Who can and cannot use Tinidazol?

This section describes official population eligibility and non-eligibility for Tinidazole, strictly based on government regulatory documents.


Absolute Contraindications

Tinidazole is strictly contraindicated in patients with a history of hypersensitivity to Tinidazole or any other nitroimidazole derivatives. It is also prohibited for patients diagnosed with Cockayne syndrome. Some regulatory sources list contraindications for patients with or with a history of blood dyscrasias or organic neurological disorders.

Age and Physiological Restrictions

  • Pediatrics: Use is not established for children 3 years of age and younger. Use in older children is limited to specific infections (giardiasis and amebiasis).
  • Pregnancy: Use is contraindicated during the first trimester. In later trimesters, use is permitted only if potential benefits outweigh possible risks.
  • Lactation: Breastfeeding is contraindicated unless interrupted for a minimum of 72 hours after the final dose.

Conditions Requiring Caution

Use requires caution in patients with severe hepatic impairment (liver disease) and those with a history of neurological issues, such as seizures or peripheral neuropathy. Older adults require cautious dose selection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tinidazole is defined by three primary mechanisms documented in government regulatory sources: metabolic exposure modification, pharmacodynamic potentiation, and a critical food/substance restriction.


Documented Interaction Patterns

Classification Interacting Entity Official Regulatory Statement
Contraindicated Alcohol (Ethanol) Must be strictly avoided during therapy and for at least 72 hours after the final dose due to the risk of a severe disulfiram-like reaction (e.g., flushing, vomiting).
Pharmacokinetic CYP3A4 Inhibitors (e.g., Cimetidine, Ketoconazole) Co-administration may increase Tinidazole plasma concentrations, potentially raising the risk of adverse reactions.
Pharmacokinetic CYP3A4 Inducers (e.g., Phenytoin, Rifampin) May decrease Tinidazole plasma concentrations, which may reduce its overall systemic exposure.
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin) Co-administration may potentiate the anticoagulant effect; documented monitoring of Prothrombin Time/INR is required.

Exposure and Clearance Modifications

Tinidazole is officially documented to influence the clearance of other medicines. For example, co-administration may increase the plasma concentration of Phenytoin and Lithium. Furthermore, Tinidazole may decrease the clearance of Fluorouracil, which increases that drug's systemic exposure. This potential for altered drug levels requires caution, particularly in populations with slow clearance, such as those with severe hepatic impairment, as noted in the regulatory labeling.

Mechanism of Action

Selective Mechanism of Action

Tinidazole functions as an inactive prodrug, initiating its mechanism by exploiting the unique internal biochemistry of susceptible anaerobic microorganisms. The drug relies on specific low-redox potential proteins, such as ferredoxins and Pyruvate Ferredoxin Oxidoreductase (PFOR), which are components of the anaerobic electron transport system. These enzymes facilitate the chemical reduction of the drug's nitro group ( -NO2), rapidly generating highly reactive, short-lived, and cytotoxic nitro radical anions ( -NO2bullet-).

Once formed, the radical intermediates target the microorganism's core genetic material, the DNA. The radicals covalently bind to the DNA strands, resulting in strand breaks and structural alteration of the double helix. This damage leads directly to the complete inhibition of nucleic acid synthesis and repair within the target cell. This cascade results in microbial cell death (bactericidal/protozoacidal effect), which is the final physiological consequence of the mechanism.

The mechanism is strictly constrained by oxygen inhibition, as the presence of O2 competes for electrons, preventing the necessary bioactivation cascade and limiting the mechanism's function to low-oxygen environments.

Dosage and Administration Information

Tinidazole is administered exclusively by the oral route, available as tablets in 250 mg and 500 mg strengths. For patients unable to swallow tablets, the medicine may be extemporaneously compounded into an oral suspension. A key requirement for proper administration is that the dose must be taken with food (during or immediately after a meal) to standardize its intake.

Usage patterns for Tinidazole are characterized by short-term courses and a once-daily frequency for multi-day regimens. For protozoal infections like Giardiasis and Trichomoniasis, a single 2 g dose is commonly used. Multi-day regimens are employed for other conditions, such as 2 g once daily for three to five days for Amebic Liver Abscess, or 1 g once daily for five days for certain Bacterial Vaginosis regimens. The total duration of use for all labeled indications typically does not exceed five days.

Population Standard Administration Guidance
Pediatric (Age ge 3 years) Dosing is weight-based (50 mg/kg) up to a maximum of 2 g per dose or day for protozoal infections.
Renal Impairment No dose adjustment is generally necessary, but a supplemental half-dose is required post-hemodialysis.

The administration protocol for Trichomoniasis includes the procedural step that the sexual partner should also be treated simultaneously. When a dose is missed, the patient should take the missed dose as soon as remembered, or omit it if the next scheduled dose is due shortly.

Recent Clinical Evidence

Research evidence / Overview of studies for Tinidazol

This section provides an overview of the types of clinical studies that have been conducted for Tinidazole, detailing what was measured, the populations involved, and where research remains limited, strictly based on official regulatory and scientific literature.


Evidence for Use in Trichomoniasis and Bacterial Vaginosis

Research evaluating the medicine for Trichomoniasis and Bacterial Vaginosis (BV) often relies on Randomized Controlled Trials (RCTs) and systematic reviews. Studies were relevant in trials assessing short-term or episodic symptom patterns.

For Trichomoniasis, research examined outcomes related to microbiological status and clinical status in adults and adolescents, including non-pregnant women and their sexual partners. For Bacterial Vaginosis, high-quality trials reported measurements of clinical outcomes compared directly against an inactive placebo, assessing therapeutic status defined by the absence of specific diagnostic signs.

What remains uncertain for these indications is the scarcity of published randomized trials comparing certain regimens specifically in men for trichomoniasis. For both indications, limited information for long-term outcomes is available regarding the incidence of recurrence over periods greater than one month.


Evidence for Use in Giardiasis

This evidence base is constructed from Randomized Controlled Trials (RCTs), Systematic Reviews, and Network Meta-analyses (NMAs). These studies monitored outcomes linked to gastrointestinal discomfort and systemic imbalance in both children and adults.

Research examined both parasitological status and the resolution of clinical symptoms. Systematic reviews reported measurements of parasitological outcomes from trials examining the drug. The evidence quality varies across studies, as many older trials were open-label (non-blinded). Concerns regarding the potential issue of drug resistance are noted as a research gap.


Evidence in Special Populations and Uncertainties

Research has explored the use in certain subgroups, including children for the protozoal infections (Giardiasis and Amebiasis). However, data for certain groups remain insufficient. For the amebiasis indications, limited information is available for children regarding treatment courses that extend beyond short, defined durations.

Overall, the follow-up durations were limited across many key studies, meaning long-term effects are not fully established. Furthermore, comparative evidence is lacking in terms of direct head-to-head trials against other standard treatments using the exact recommended dosing of both agents.

Key Studies & References

  1. TINIDAZOLE tablet: Clinical Pharmacology and Indications

Frequently Asked Questions (FAQ)

Common questions about Tinidazol (FAQ)


Q: What is the main difference between Tinidazol and Metronidazol?

According to official information, Tinidazol is chemically related to metronidazole, as both belong to the nitroimidazole class. A key difference described in authoritative medical resources is that Tinidazol has a longer elimination half-life. This characteristic is described as a factor allowing for less frequent dosing in the official regimens of Tinidazol.


Q: How long does Tinidazol stay in your system after you stop taking it?

Regulatory information detailing the drug’s processing in the body indicates that the elimination half-life is approximately 12 to 14 hours. The half-life refers to the time it takes for the concentration of the medicine in the body to decrease by half.


Q: Is there any evidence that Tinidazol can affect sleep patterns?

The official product information lists effects such as headache and fatigue/malaise, but changes to sleep patterns are not directly listed as a common or specific adverse reaction. The labeling does include central nervous system (CNS) effects that are reported in rare instances.


Q: Are there any long-term effects associated with using Tinidazol?

The official product information states that chronic use is to be avoided as a precautionary measure. This restriction is primarily due to the potential for genotoxicity—damage to the genetic material (DNA)—which has been observed in studies of related drugs. Because of this, the medicine's use is limited to the approved short-term courses for its labeled indications.


Q: Do official documents mention Tinidazol being used for any conditions outside of the main list?

Official regulatory documents state that the use of Tinidazol must be limited strictly to its approved indications. These approved uses include conditions such as trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis. No other conditions are authorized for treatment in the official labeling.


Q: How does the action of Tinidazol compare to other similar antibiotics, generally speaking?

Tinidazol is classified as an antiprotozoal and antibacterial agent, known specifically for its mechanism of action against anaerobic microorganisms. The drug works by being chemically reduced inside the target cell. This activation process leads to strand breaks and damage to the microorganism's DNA, which is the action intended to stop the proliferation of targeted organisms.


Q: Are there any common tests a doctor might perform before or during treatment with Tinidazol?

While there are no routine general tests mandated for all patients, official labeling highlights the need for caution in specific populations. Testing for blood dyscrasia (blood disorders) may be indicated if there is a patient history. For patients using oral anticoagulants or certain other interacting drugs, official labeling indicates that monitoring of drug levels or blood coagulation tests may be required by a healthcare professional.


Q: Does taking Tinidazol with food change how the medicine is absorbed?

Official prescribing information advises patients to take Tinidazol with food to help minimize the occurrence of gastrointestinal side effects, such as nausea. Regulatory pharmacokinetic data indicates that food does not significantly affect the overall amount of drug absorbed into the bloodstream (oral bioavailability).


Q: Can Tinidazol cause issues with vision or hearing?

Official labeling does not explicitly list vision or hearing loss as common adverse events. However, it does warn about rare and serious neurological adverse reactions, including peripheral neuropathy (nerve damage) and dizziness. Discontinuation of therapy is required if any abnormal neurological signs emerge.


Q: Why is it important to complete the entire course of Tinidazol even if symptoms improve?

Official patient information emphasizes that the full course of therapy is specified to be completed, even if a patient begins to feel better quickly. This course of action is specified in official information to decrease the risk of the targeted microorganisms developing resistance to the drug and may also help prevent the recurrence of the infection.


Q: Can the effectiveness of Tinidazol be reduced by certain dietary habits?

The effectiveness of the medicine can be reduced by avoiding food when taking the dose, as taking it with food is specified for managing side effects. Official documents note that alcohol is strictly contraindicated during therapy due to the risk of a severe systemic reaction. Effectiveness can also be reduced by concurrent use of certain liver enzyme-inducing drugs (CYP3A4 inducers).


Q: Are there specific symptoms that warrant immediate medical attention while on Tinidazol?

Official safety constraints define certain serious events that require prompt medical review and discontinuation of the medicine. These include the development of any abnormal neurological signs (e.g., peripheral neuropathy, convulsions) or signs of severe acute hypersensitivity reactions (e.g., Stevens-Johnson Syndrome). These symptoms warrant prompt attention from a healthcare professional.


Q: What is the recommended approach if I am already taking medication for chronic disease?

Official regulatory documents caution that Tinidazol interacts with several classes of chronic drugs, including oral anticoagulants, lithium, and certain medicines for seizure disorders (e.g., phenytoin). Official guidance indicates that due to the potential for altered drug levels, the supervising healthcare professional may need to monitor drug levels or adjust the dosage of the chronic medicine during co-administration.


Q: Is there a risk of developing a yeast infection after taking Tinidazol?

The official product labeling indicates that use of Tinidazol may result in the development of vaginal candidiasis (a type of yeast infection). If this occurs, an antifungal agent may be considered for treatment.


Q: Can Tinidazol be taken at the same time as cold or flu medicine?

Regulatory documents state that Tinidazol's metabolism can be affected by medicines that inhibit or induce the CYP3A4 liver enzyme system. Because over-the-counter cold and flu preparations often contain multiple ingredients, the ingredients of any such medicine should be reviewed to check for potential interacting agents.

How should Tinidazol be stored and disposed of?

How to Store and Dispose of Tinidazole

Storage Temperature and Environment

Tinidazole tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted brief excursions up to 30 C. The medicine must be protected from light and kept from freezing.

Packaging and Child Safety

Tablets should be dispensed in a well-closed, child-resistant container and must be kept out of the reach of children. If the tablets are used to compound an oral suspension, the liquid is stable for 7 days when stored at room temperature.

Disposal Instructions

Do not keep outdated medicine or medicine that is no longer needed. Unused or expired Tinidazole should be disposed of in accordance with local requirements, and a healthcare professional should be consulted for proper disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tinidazol found in:

A-Z Index: